Hypertension management in patients with cardiovascular comorbidities - Archive ouverte HAL
Article Dans Une Revue European Heart Journal Année : 2023

Hypertension management in patients with cardiovascular comorbidities

Deepak L Bhatt
Koon K Teo
Raymond R Townsend
Michael A Weber

Résumé

Abstract Arterial hypertension is a leading cause of death globally. Due to ageing, the rising incidence of obesity, and socioeconomic and environmental changes, its incidence increases worldwide. Hypertension commonly coexists with Type 2 diabetes, obesity, dyslipidaemia, sedentary lifestyle, and smoking leading to risk amplification. Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Guidelines recommend dual- and triple-combination therapies using renin–angiotensin system blockers, calcium channel blockers, and/or a diuretic. Comorbidities often complicate management. New drugs such as angiotensin receptor-neprilysin inhibitors, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists improve CV and renal outcomes. Catheter-based renal denervation could offer an alternative treatment option in comorbid hypertension associated with increased sympathetic nerve activity. This review summarises the latest clinical evidence for managing hypertension with CV comorbidities.
Fichier principal
Vignette du fichier
2022-Lauder-Eur Heart J.pdf (2.12 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04051779 , version 1 (30-03-2023)

Licence

Identifiants

Citer

Lucas Lauder, Felix Mahfoud, Michel Azizi, Deepak L Bhatt, Sebastian Ewen, et al.. Hypertension management in patients with cardiovascular comorbidities. European Heart Journal, 2023, 44 (23), pp.2066-2077. ⟨10.1093/eurheartj/ehac395⟩. ⟨hal-04051779⟩
43 Consultations
352 Téléchargements

Partager

More